ACKNOWLEDGEMENTS
We thank CERCA Program / Generalitat de Catalunya for their institutional support. We wish also to thank all the members of the ICO Hereditary Cancer Program.
REFERENCES
Abou Tayoun, A. N., Pesaran, T., DiStefano, M. T., Oza, A., Rehm, H. L., Biesecker, L. G., . . . SVI), C. S. V. I. W. G. C. (2018). Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. Hum Mutat, 39 (11), 1517-1524. doi:10.1002/humu.23626
AlDubayan, S. H., Pyle, L. C., Gamulin, M., Kulis, T., Moore, N. D., Taylor-Weiner, A., . . . Lessel, D. (2019). Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors. JAMA Oncol . doi:10.1001/jamaoncol.2018.6477
Balmaña, J., Digiovanni, L., Gaddam, P., Walsh, M. F., Joseph, V., Stadler, Z. K., . . . Domchek, S. M. (2016). Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. J Clin Oncol, 34 (34), 4071-4078. doi:10.1200/JCO.2016.68.4316
Bartek, J., Falck, J., & Lukas, J. (2001). CHK2 kinase–a busy messenger. Nat Rev Mol Cell Biol, 2 (12), 877-886.
Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C., Shannon, K. E., . . . Haber, D. A. (1999). Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science, 286 (5449), 2528-2531.
Bellosillo, B., Tusquets, I., Longarón, R., Pérez-Lezaun, A., Bellet, M., Fabregat, X., . . . Solé, F. (2005). Absence of CHEK2 mutations in Spanish families with hereditary breast cancer. Cancer Genet Cytogenet, 161 (1), 93-95. doi:10.1016/j.cancergencyto.2005.01.016
ClinGen-TP53_Expert_Panel. (2019, August 6, 2020). TP53 Rule Specifications for the ACMG/AMP
Variant Curation Guidelines. Retrieved fromhttps://www.clinicalgenome.org/affiliation/50013
Couch, F. J., Shimelis, H., Hu, C., Hart, S. N., Polley, E. C., Na, J., . . . Dolinsky, J. S. (2017). Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol, 3 (9), 1190-1196. doi:10.1001/jamaoncol.2017.0424
Cybulski, C., Gorski, B., Huzarski, T., Masojc, B., Mierzejewski, M., Debniak, T., . . . Lubinski, J. (2004). CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet, 75 (6), 1131-1135.
Cybulski, C., Wokolorczyk, D., Huzarski, T., Byrski, T., Gronwald, J., Gorski, B., . . . Lubinski, J. (2007). A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. Breast Cancer Res Treat, 102 (1), 119-122.
Decker, B., Allen, J., Luccarini, C., Pooley, K. A., Shah, M., Bolla, M. K., . . . Easton, D. F. (2017). Rare, protein-truncating variants in.J Med Genet, 54 (11), 732-741. doi:10.1136/jmedgenet-2017-104588
Easton, D. F., Pharoah, P. D. P., Antoniou, A. C., Tischkowitz, M., Tavtigian, S. V., Nathanson, K. L., . . . Foulkes, W. D. (2015). Gene-panel sequencing and the prediction of breast-cancer risk.The New England journal of medicine, 372 (23), 2243-2257. doi:10.1056/NEJMsr1501341
Fachal, L., Santamariña, M., Blanco, A., Carracedo, A., & Vega, A. (2013). CHEK2 c.1100delC mutation among non-BRCA1/2 Spanish hereditary breast cancer families. Clin Transl Oncol, 15 (2), 164-165. doi:10.1007/s12094-012-0967-z
Feliubadaló, L., Tonda, R., Gausachs, M., Trotta, J. R., Castellanos, E., López-Doriga, A., . . . Lázaro, C. (2017). Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer. Sci Rep, 7 , 37984. doi:10.1038/srep37984
Fostira, F., Kostantopoulou, I., Apostolou, P., Papamentzelopoulou, M. S., Papadimitriou, C., Faliakou, E., . . . Yannoukakos, D. (2020). One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene. J Med Genet, 57 (1), 53-61. doi:10.1136/jmedgenet-2019-106189
Gutiérrez-Enríquez, S., Balmaña, J., Baiget, M., & Díez, O. (2008). Detection of the CHEK2 1100delC mutation by MLPA BRCA1/2 analysis: a worthwhile strategy for its clinical applicability in 1100delC low-frequency populations? Breast Cancer Res Treat, 107 (3), 455-457. doi:10.1007/s10549-007-9555-2
Han, F. F., Guo, C. L., & Liu, L. H. (2013). The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis.DNA Cell Biol, 32 (6), 329-335. doi:10.1089/dna.2013.1970
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., . . . MacArthur, D. G. (2019). Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. bioRxiv , 531210. doi:10.1101/531210
Katona, B. W., Yurgelun, M. B., Garber, J. E., Offit, K., Domchek, S. M., Robson, M. E., & Stadler, Z. K. (2018). A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genet Med, 20 (11), 1324-1327. doi:10.1038/gim.2018.12
Kopanos, C., Tsiolkas, V., Kouris, A., Chapple, C. E., Albarca Aguilera, M., Meyer, R., & Massouras, A. (2018). VarSome: the human genomic variant search engine. Bioinformatics, 35 (11), 1978-1980. doi:10.1093/bioinformatics/bty897
Kraus, C., Hoyer, J., Vasileiou, G., Wunderle, M., Lux, M. P., Fasching, P. A., . . . Reis, A. (2017). Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2. Int J Cancer, 140 (1), 95-102. doi:10.1002/ijc.30428
Liang, M., Zhang, Y., Sun, C., Rizeq, F. K., Min, M., Shi, T., & Sun, Y. (2018). Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis. Mol Diagn Ther . doi:10.1007/s40291-018-0344-x
M Kriege, A. H., A Jager, P E A Huijts, E M Berns, A M Sieuwerts, M E Meijer-van Gelder,, & J M Collée, P. D., M J Hooning, J W M Martens and C Seynaeve. (2014). Survival and contralateral breast cancer in
CHEK2 1100delC breast cancer patients:
impact of adjuvant chemotherapy. British Journal of Cancer, 111 , 1004–1013. doi:10.1038/bjc.2014.306
Martínez-Bouzas, C., Beristain, E., Guerra, I., Gorostiaga, J., Mendizabal, J. L., De-Pablo, J. L., . . . Tejada, M. I. (2007). CHEK2 1100delC is present in familial breast cancer cases of the Basque Country. Breast Cancer Res Treat, 103 (1), 111-113. doi:10.1007/s10549-006-9351-4
Matsuoka, S., Rotman, G., Ogawa, A., Shiloh, Y., Tamai, K., & Elledge, S. J. (2000). Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci U S A, 97 (19), 10389-10394.
Meijers-Heijboer, H., van den Ouweland, A., Klijn, J., Wasielewski, M., de Snoo, A., Oldenburg, R., . . . Stratton, M. R. (2002). Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet, 31 (1), 55-59.
Meijers-Heijboer, H., Wijnen, J., Vasen, H., Wasielewski, M., Wagner, A., Hollestelle, A., . . . Schutte, M. (2003). The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet, 72 (5), 1308-1314.
Oldenburg, R. A., Kroeze-Jansema, K., Kraan, J., Morreau, H., Klijn, J. G., Hoogerbrugge, N., . . . Devilee, P. (2003). The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res, 63 (23), 8153-8157.
Plon, S. E., Cooper, H. P., Parks, B., Dhar, S. U., Kelly, P. A., Weinberg, A. D., . . . Hilsenbeck, S. (2008). Genetic testing and cancer risk management recommendations by physicians for at-risk relatives.Genet Med, 13 (2), 148-154.
Richards, C. S., Bale, S., Bellissimo, D. B., Das, S., Grody, W. W., Hegde, M. R., . . . Ward, B. E. (2008). ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genetics in medicine : official journal of the American College of Medical Genetics, 10 (4), 294-300. doi:10.1097/GIM.0b013e31816b5cae
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., . . . Rehm, H. L. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med, 17 (5), 405-424. doi:10.1038/gim.2015.30
Schmidt, M. K., Hogervorst, F., van Hien, R., Cornelissen, S., Broeks, A., Adank, M. A., . . . Easton, D. F. (2016). Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. J Clin Oncol, 34 (23), 2750-2760. doi:10.1200/JCO.2016.66.5844
Senol-Cosar, O., Schmidt, R. J., Qian, E., Hoskinson, D., Mason-Suares, H., Funke, B., & Lebo, M. S. (2019). Considerations for clinical curation, classification, and reporting of low-penetrance and low effect size variants associated with disease risk. Genet Med, 21 (12), 2765-2773. doi:10.1038/s41436-019-0560-8
Spurdle, A. B., Healey, S., Devereau, A., Hogervorst, F. B. L., Monteiro, A. N. A., Nathanson, K. L., . . . Enigma. (2012). ENIGMA–evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Human mutation, 33 (1), 2-7. doi:10.1002/humu.21628
Stradella, A., Del Valle, J., Rofes, P., Feliubadaló, L., Grau Garces, È., Velasco, À., . . . Lázaro, C. (2018). Does multilocus inherited neoplasia alleles syndrome have severe clinical expression? J Med Genet . doi:10.1136/jmedgenet-2018-105700
Szymanska-Pasternak, J., Szymanska, A., Medrek, K., Imyanitov, E. N., Cybulski, C., Gorski, B., . . . Lubinski, J. (2006). CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors.Gynecol Oncol, 102 (3), 429-431. doi:10.1016/j.ygyno.2006.05.040
Tavtigian, S. V., Greenblatt, M. S., Harrison, S. M., Nussbaum, R. L., Prabhu, S. A., Boucher, K. M., . . . SVI), C. S. V. I. W. G. C. (2018). Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. Genet Med, 20 (9), 1054-1060. doi:10.1038/gim.2017.210
Taylor, A., Brady, A. F., Frayling, I. M., Hanson, H., Tischkowitz, M., Turnbull, C., . . . (UK-CGG), U. C. G. G. (2018). Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group. J Med Genet, 55 (6), 372-377. doi:10.1136/jmedgenet-2017-105188
Wu, X., Webster, S. R., & Chen, J. (2001). Characterization of tumor-associated Chk2 mutations. J Biol Chem, 276 (4), 2971-2974.
Zannini, L., Delia, D., & Buscemi, G. (2014). CHK2 kinase in the DNA damage response and beyond. J Mol Cell Biol, 6 (6), 442-457. doi:10.1093/jmcb/mju045